Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atara Biotherapeutics (ATRA) Depreciation and Depletion (2022 - 2025)

Atara Biotherapeutics' Depreciation and Depletion history spans 4 years, with the latest figure at $100000.0 for Q4 2025.

  • For Q4 2025, Depreciation and Depletion fell 80.0% year-over-year to $100000.0; the TTM value through Dec 2025 reached $400000.0, down 85.19%, while the annual FY2025 figure was $400000.0, 85.19% down from the prior year.
  • Depreciation and Depletion reached $100000.0 in Q4 2025 per ATRA's latest filing, down from $300000.0 in the prior quarter.
  • In the past five years, Depreciation and Depletion ranged from a high of $1.5 million in Q1 2022 to a low of $100000.0 in Q4 2025.
  • Average Depreciation and Depletion over 4 years is $828571.4, with a median of $900000.0 recorded in 2022.
  • Peak YoY movement for Depreciation and Depletion: changed 0.0% in 2023, then tumbled 80.0% in 2025.
  • A 4-year view of Depreciation and Depletion shows it stood at $900000.0 in 2022, then changed by 0.0% to $900000.0 in 2023, then plummeted by 44.44% to $500000.0 in 2024, then crashed by 80.0% to $100000.0 in 2025.
  • Per Business Quant, the three most recent readings for ATRA's Depreciation and Depletion are $100000.0 (Q4 2025), $300000.0 (Q1 2025), and $500000.0 (Q4 2024).